Browsing Tag
BAFF APRIL inhibitor
2 posts
Can povetacicept reshape autoimmune kidney care? Vertex Pharmaceuticals’ RUBY-3 trial shows promise
Vertex’s RUBY-3 trial shows strong 48-week data for povetacicept in IgAN and pMN. Find out how this sets the stage for late-stage trials and regulatory filings.
Aurinia Pharmaceuticals to present AUR200 Phase 1 trial data on June 30, 2025 in key webcast update
Aurinia Pharmaceuticals will release AUR200 Phase 1 results on June 30, 2025. Analysts await autoimmune insights. Join the webcast for full trial data.